A
A
    Global websites
    Local websites
    language header world map

    United in our commitment to
    improve the lives of patients.

    Watch the
    story
    (01:30)
    WE ARE HERE WITH YOU

    Reaching Patients Through Immunology Innovation

    The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.

    The infinity sign symbolizes our commitment to science and patients; it has no bounds.

    Patients

    infinity-gif

    Where we operate

    Innovation

    Together We Discover

    We know that leaps in progress will come from collaboration and incorporating innovation into every step. We embrace the power of the collective – together we are better.

    Innovation

    Our Discoveries

    At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.

    Our discoveries

    Melissa's story

    We Hear You

    " Early on I learned that this disease is just as mental as it is physical. "

    Patient story
    Eri's story

    We Hear You

    " When I was younger they told me I would never walk again, but I grew up playing basketball... read more

    Patient story

    Doing the Unthinkable

    argenx comes from the story of the Argonauts – we want to achieve the unthinkable together.

    Dare To Do More

    We dare you to see where argenx can take your career next.

    List of jobs

    Pipeline

    Product Candidates

    Our proprietary portfolio is focused on first-in-class product candidates engineered in collaboration with our academic partners to help translate immunology breakthroughs into medicines.

    Pipeline

    Our Pride

    Efgartigimod

    Target:
    FcRn

    We are investigating efgartigimod for the treatment of several severe autoimmune diseases. Efgartigimod is marketed as VYVGART for the treatment of generalized myasthenia gravis (gMG) and VYVGART Hytrulo for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

    Designed to block FcRn and reduce IgGs, efgartigimod could be a rational approach to treating diseases where IgG antibodies are pathogenic or disease-causing.

    See program

        

      

    Empasiprubart

    Target:
    C2

    We are evaluating empasiprubart for the treatment of severe IgM driven auto-immune diseases.

    Empasiprubart is designed to be a humanized sweeping antibody intended to inhibit the function of C2 and downstream complement activation.

    See program